title: Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease.
authors.forename: Ute
authors.initials: U
authors.lastname: Teichgräber
authors.forename: Imke
authors.initials: I
authors.lastname: Atreya
authors.forename: Raja
authors.initials: R
authors.lastname: Atreya
authors.forename: Matthias
authors.initials: M
authors.lastname: Schwab
authors.forename: Markus F
authors.initials: MF
authors.lastname: Neurath
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001379:Azathioprine / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006160:Guanosine Triphosphate / Q000031:analogs & derivatives* / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D011379:Prognosis; D013873:Thionucleotides / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D013873:Thionucleotides; D014409:Tumor Necrosis Factor-alpha; C032827:6-thioguanosine 5'-triphosphate; D006160:Guanosine Triphosphate; D000069285:Infliximab; D001379:Azathioprine